Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Ebixa opvejer risiciene til behandling af patienter med moderat til svær Alzheimers sygdom.
The Committee for Medicinal Products for Human Use (CHMP) decided that Ebixa’ s benefits are greater than its risks for the treatment of patients with moderate to severe Alzheimer’ s disease.